Trial Profile
A Randomized Trial Of Raloxifene Plus Zoladex For Prevention Of Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Goserelin (Primary) ; Raloxifene (Primary)
- Indications Breast cancer; Osteoporosis
- Focus Therapeutic Use
- Acronyms IBIS-RAZOR; RAZOR
- 08 Dec 2012 Results presented at the 35th Annual San Antonio Breast Cancer Symposium.
- 02 Dec 2011 Actual end date (May 2005) added as reported by ISRCTN: Current Controlled Trials.
- 16 May 2007 Status changed from recruiting to completed.